Key facts
- This page summarizes Roystone Capital Management LP's Form 3 filing for VAPOTHERM INC.
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Feb 2023, 12:34.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
Additional SEC filing notes
Footnote F1
The reported securities and warrants are owned directly by Guines LLC ("Guines") and may be deemed to be indirectly beneficially owned by (i) Roystone Capital Management LP ("Roystone"), the investment adviser to Guines (ii) Roystone Capital Holdings LLC ("Holdings"), the general partner of Roystone and (iii) Richard Barrera, the managing member of Holdings. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F2
The reported securities are owned directly by Roystone Capital Master Fund Ltd. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Roystone, the investment adviser to the Master Fund (ii) Holdings, the general partner of Roystone and (iii) Richard Barrera, the managing member of Holdings. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F3
The reported warrants are each exercisable for one share of Common Stock, $0.001 par value per share. The foregoing description of the warrants does not purport to be complete and is subject to and qualified in its entirety by reference to the Form of Warrant, incorporated as Exhibit 4.2 to the Issuer's 8-K filed on February 8, 2023, which is incorporated by reference.